The National Institutes of Health (NIH) awarded a research team at George Washington (GW), Yale, and Duke Universities $7.8 million to establish a rare disease network for Myasthenia Gravis. The team is led by Henry Kaminiski
, MD (GW) and includes Linda Kusner
, PhD (GW), Alison Hall
, PhD (GW), Jeffrey Guptill
, MD (Duke), Richard Nowak
, MD (Yale), and Kevin O'Connor
, PhD (Yale) as project leaders and executive steering committee members. This consortium will be one part of the larger Rare Diseases Clinical Research Network
(RDCRN), funded by multiple NIH Institutes and Centers and led by NIH’s National Center for Advancing Translational Sciences
The new Myasthenia Gravis Network (MGNet) will include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies working together to enhance therapeutic development for this rare disease. The GW research team is also supported by commitments from the Myasthenia Gravis Foundation of America and Conquer Myasthenia Gravis. To increase the number of labs researching myasthenia gravis and aid further discovery in the field, the grant will support a career enhancement program and a pilot program. The RFAs for these programs are open to investigators at any academic institution across the country, so long as they have an MD, PhD, or equivalent.
Applicants are strongly encouraged to contact the MGNet Program Administrator to facilitate the application process (MGNet@gwu.edu).
Myasthenia Gravis Network (MGNet) Scholar Program
Applications due November 20, 2019
PI must hold an MD, PhD, or equivalent and be a clinical fellow, post-doctoral fellow, or junior faculty
Myasthenia Gravis Network (MGNet) Pilot Program
Letters of Intent due December 16, 2019
PI must hold an MD, PhD, PharmD, DDS, DVM, or equivalent and be a faculty member at an academic institution